Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:31.671Z.
Calculation as of: 2026-10-06T16:57:31.671Z.
Quote observation: 2026-10-06T16:55:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Mineralys Therapeutics, Inc.
Market Cap
$1.97B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.98B
EV/EBITDA Ratio
26.34x
TTM Avg
33.53x
3Y Avg
86.79x
5Y Avg
86.79x
Market Cap
$2.02B
EV/EBITDA Ratio
11.16x
TTM Avg
18.29x
3Y Avg
26.08x
5Y Avg
26.08x
Market Cap
$1.91B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.04B
EV/EBITDA Ratio
N/A
TTM Avg
40.61x
3Y Avg
40.61x
5Y Avg
40.61x
Market Cap
$1.90B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.97B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 26.34x | 33.53x | 86.79x | 86.79x |
| AxoGen, Inc. (AXGN)vs › | $1.96B | N/A | 616.50x | 557.10x | 557.10x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 11.16x | 18.29x | 26.08x | 26.08x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.04B | 16.04x | 20.50x | 31.95x | 75.16x |
| Immunome, Inc. (IMNM)vs › | $1.90B | N/A | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 40.61x | 40.61x | 40.61x |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | 33.62x | 35.09x | 121.98x | 105.15x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
